Durie B G, Young L A, Salmon S E
Blood. 1983 May;61(5):929-34.
Ninety-seven patients with multiple myeloma evaluated serially had both a tritiated thymidine labeling index of bone marrow plasma cells (LI%) and in vitro myeloma stem cell culture performed. Thirty-three patients with myeloma colony growth had in vitro drug sensitivity testing carried out, 18 having in addition in vitro thymidine suicide determinations. The LI% and the likelihood of in vitro myeloma colony growth were highly correlated: the higher the LI%, the more likely was colony or cluster growth (p less than 0.001). The tritiated thymidine suicide of myeloma stem cells was usually very high. There was excellent correlation between in vitro and in vivo drug sensitivity. Both pretreatment drug resistance and selective sensitivity (e.g., interferon, bisantrene, methotrexate, vinblastine) at the time of relapse were accurately detected and correlated well with survival duration (p = 0.01 Wilcoxan). Although LI% and in vitro sensitivity were clearly independent variables, a high LI% (greater than 3%) plus in vitro resistance were associated with a subsequent survival duration of less than 6 mo. The studies allowed dissection of the complex interrelationship between cell kinetics and drug sensitivity.
对97例多发性骨髓瘤患者进行了连续评估,检测了其骨髓浆细胞的氚标记胸腺嘧啶核苷标记指数(LI%),并进行了体外骨髓瘤干细胞培养。对33例有骨髓瘤集落生长的患者进行了体外药敏试验,其中18例还进行了体外胸腺嘧啶核苷自杀测定。LI%与体外骨髓瘤集落生长的可能性高度相关:LI%越高,集落或簇生长的可能性越大(p<0.001)。骨髓瘤干细胞的氚标记胸腺嘧啶核苷自杀率通常非常高。体外和体内药敏之间存在良好的相关性。复发时的预处理耐药性和选择性敏感性(如干扰素、双胺苯吖啶、甲氨蝶呤、长春碱)均能被准确检测,且与生存时间密切相关(Wilcoxan检验,p=0.01)。尽管LI%和体外敏感性显然是独立变量,但高LI%(大于3%)加上体外耐药与随后小于6个月的生存时间相关。这些研究有助于剖析细胞动力学与药敏之间复杂的相互关系。